Walach N, Guterman A, Zaidman J L, Kaufman S, Scharf S
Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel.
J Surg Oncol. 1989 Feb;40(2):85-7. doi: 10.1002/jso.2930400205.
Leukocyte alkaline phosphatase (LAP) scores in peripheral blood and plasma carcinoembryonic antigen (CEA) levels were determined in 208 breast cancer patients with nonmetastatic disease. Patients were followed until clinical manifestations of metastases appeared. Then the LAP score and CEA level were analyzed in relation to the clinical appearance of metastases. Of the 208 patients studied, 58 developed metastases during the follow-up period. The LAP scores and CEA levels of this group of patients were compared to a control group of 60 breast cancer patients who did not develop metastases. Of the two markers, LAP score seems to be considerably more useful in detecting metastatic disease.
对208例非转移性乳腺癌患者测定了外周血白细胞碱性磷酸酶（LAP）评分和血浆癌胚抗原（CEA）水平。对患者进行随访，直至出现转移的临床表现。然后分析LAP评分和CEA水平与转移临床表现的关系。在研究的208例患者中，58例在随访期间出现转移。将这组患者的LAP评分和CEA水平与60例未发生转移的乳腺癌患者对照组进行比较。在这两种标志物中，LAP评分在检测转移性疾病方面似乎更有用得多。
